MarketCap
Facebook
X
Telegram
Novavax Market Cap | NVAX
As of October 26, 2026 Novavax has a market cap of $ 1.53 B
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Novavax
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.85 B | 1.08 B | 444 M | 727 M | 6.2 B | 13.3 B | 169 M | 843 M | 600 M | 347 M | 1.35 B | 1.76 B | 1.02 B | 234 M | 173 M | 4.76 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.3 B | 4.76 M | 1.88 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Catalyst Biosciences
CBIO
|
999 M | $ 12.6 | -1.72 % | $ 1.13 B |  USA |
 |
Inozyme Pharma
INZY
|
297 M | - | - | $ 207 M | USA |
 |
BioCardia
BCDA
|
8.07 M | $ 0.9 | -2.29 % | $ 6 M | USA |
 |
Orgenesis
ORGS
|
1.45 M | - | -33.86 % | $ 61.2 M | USA |
 |
Codiak BioSciences
CDAK
|
243 M | - | -55.98 % | $ 2.15 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
160 M | - | - | $ 169 M | USA |
 |
Sierra Oncology
SRRA
|
288 M | - | -0.05 % | $ 1.34 B |  Canada |
 |
Atea Pharmaceuticals
AVIR
|
426 M | $ 4.2 | 3.84 % | $ 342 M | USA |
 |
Vaccinex
VCNX
|
2.96 M | - | -61.37 % | $ 654 K | USA |
 |
Sage Therapeutics
SAGE
|
434 M | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
1.36 B | - | - | $ 1.62 B |  Israel |
 |
Nymox Pharmaceutical Corporation
NYMX
|
18.7 M | - | -19.68 % | $ 18.4 M | Canada |
 |
Forma Therapeutics Holdings
FMTX
|
467 M | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
5.96 B | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
25.2 B | - | - | $ 26.6 B |  Irlanda |
 |
Paratek Pharmaceuticals
PRTK
|
81 M | - | - | $ 121 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
427 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
16.7 M | - | -24.86 % | $ 820 K | USA |
 |
Cerus Corporation
CERS
|
496 M | $ 2.4 | 3.22 % | $ 457 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
664 K | - | -11.43 % | $ 502 K | USA |
 |
Adverum Biotechnologies
ADVM
|
76.4 M | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
28.1 M | - | -33.41 % | $ 3.37 M | USA |
 |
Cullinan Management
CGEM
|
898 M | $ 14.65 | 1.95 % | $ 883 M | USA |
 |
iTeos Therapeutics
ITOS
|
293 M | - | - | $ 411 M | USA |
 |
CymaBay Therapeutics
CBAY
|
3.43 B | - | - | $ 3.45 B | USA |
 |
Seelos Therapeutics
SEEL
|
5.44 M | - | -47.76 % | $ 6.27 M | USA |
 |
Cabaletta Bio
CABA
|
283 M | $ 1.36 | -7.48 % | $ 137 M | USA |
 |
Timber Pharmaceuticals
TMBR
|
4.43 M | - | - | $ 717 K | USA |
 |
Coherus BioSciences
CHRS
|
226 M | $ 1.01 | -1.88 % | $ 118 M | USA |
 |
Advaxis
ADXS
|
1.87 M | - | -9.65 % | $ 45.9 M | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
6.68 B | - | - | $ 7.29 B | USA |
 |
Kiromic BioPharma
KRBP
|
4.83 M | - | 6.61 % | $ 3.08 M | USA |
 |
Theravance Biopharma
TBPH
|
742 M | $ 17.03 | 0.03 % | $ 857 M |  Cayman-islands |
 |
Cocrystal Pharma
COCP
|
11.4 M | $ 0.99 | 4.32 % | $ 11.2 M | USA |
 |
Collegium Pharmaceutical
COLL
|
1.4 B | $ 23.27 | 1.35 % | $ 737 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
3.75 B | $ 87.62 | 2.04 % | $ 9.1 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 4.03 | -0.5 % | $ 53.7 M | USA |
 |
CorMedix
CRMD
|
456 K | $ 8.01 | 1.91 % | $ 577 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
4.39 B | $ 48.85 | -1.1 % | $ 4.39 B |  Schweiz |
|
Champions Oncology
CSBR
|
83.8 M | $ 4.8 | 1.69 % | $ 66.4 M | USA |
 |
CytomX Therapeutics
CTMX
|
931 M | $ 2.23 | -3.88 % | $ 308 M | USA |
 |
CEL-SCI Corporation
CVM
|
19.9 M | $ 1.54 | -5.52 % | $ 12.3 M | USA |
 |
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
49.1 M | - | -10.95 % | $ 876 K | USA |
 |
Cytokinetics, Incorporated
CYTK
|
7.55 M | $ 61.14 | -0.16 % | $ 7.34 M | USA |
 |
ChemoCentryx
CCXI
|
1.88 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M | USA |
 |
DBV Technologies S.A.
DBVT
|
2.82 B | $ 9.91 | 1.64 % | $ 1.38 B |  France |
 |
Zosano Pharma Corporation
ZSAN
|
52.7 M | - | 7.23 % | $ 2.72 M | USA |
 |
Spectrum Pharmaceuticals
SPPI
|
123 M | - | - | $ 189 M | USA |